Takeda Pharmaceuticals USA and Cognition Kit have demonstrated the use of an Apple Watch wearable to monitor and evaluate cognition and mood in patients suffering from major depressive disorder (MDD).
Cognition Kit, a joint venture between Cambridge Cognition and Ctrl Group, designed the Apple Watch application (app) to facilitate patient assessment and monitoring outside of the lab.
The patients were found to be 95% compliant with mood evaluation and 96% for cognition monitoring on a daily basis with the wearable device.
The prospective observational study involved administration of brief cognitive and mood tests on an Apple Watch for 30 subjects aged 18-65 years and prescribed with antidepressant monotherapy.
Co-primary objectives of the study included feasibility and compliance of mood and cognitive measures on wearable technology, and comparison of the measures with standard neuropsychological tests and patient-reported outcomes on the symptoms of depression.
The abbreviated assessments through the wearable device were comparable with objective Cambridge Neuropsychological Test Automated Battery (CANTAB) cognitive tests and full-length PHQ-9 and PDQ-D patient-reported outcomes carried out in the first, third and sixth weeks.
Furthermore, the results did not indicate any adverse events during the study period.
Takeda Pharmaceuticals USA external partnerships vice-president Nicole Mowad-Nassar said: “Technology may allow us to create real-time objective measurements for assessing effects in depression that could transform patient care by increasing our ability to estimate clinical conditions and support earlier engagement between the patient and clinician.
“We are encouraged by the study results and look forward to learning more about the intersection of technology and healthcare.”